Skip to content

Oliceridine combined with propofol-etomidate sedation in geriatric outpatients undergoing painless gastroscopy: a randomized controlled trial

Oliceridine combined with propofol-etomidate sedation in geriatric outpatients undergoing painless gastroscopy: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098774
Enrollment
Unknown
Registered
2025-03-13
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Oliceridine combined with propofol-etomidate group(OPE group):Oliceridine combined with propofol-etomidate sedation
Dezocine combined with propofol-etomidate group(DPE group):Dezocine combined with propofol-etomidate sedation

Sponsors

Weihai Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Elderly outpatients over 65 years of age; 2.ASA classification I to III; 3.Received painless gastroenteroscopy; 4. Patients gave informed consent and voluntarily participated in this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with known allergy to therapeutic drugs, patients taking opioids or NSAIDs within 2 d prior to the examination with a history of recovery from anaesthesia for unusual surgery; 2. Those with a history of severe cardiac, cerebrovascular, respiratory, hepatic, renal and metabolic disorders, severe ischemic heart disease, and chronic pain; 3. Those with significant airway difficulties, nasopharyngeal or oesophageal cancer, and psychiatric disorders; 4. Those with a history of acute respiratory tract infections within 2 weeks that have not been history of acute respiratory infection within 2 weeks without cure; 5. those with neuromuscular system diseases, mental illness; 6. subjects who explicitly refused to participate in this study; 7. subjects who, in the opinion of the investigator, are not suitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
The dosage of sedative drugs, including induction dosage, additional dosage, and total dosage;

Secondary

MeasureTime frame
Blood Flow Dynamics Indicators During Gastrointestinal Endoscopy;Indicators of Adverse Reactions During Gastrointestinal Endoscopy Examination;Indicators related to patient recovery after gastrointestinal endoscopy;Patients and related indicators of gastrointestinal endoscopy (general information of patients);

Countries

China

Contacts

Public ContactNing Xu

Weihai Central Hospital

xuning01@163.com+86 131 5357 5266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 31, 2026